PH12018502586A1 - Anti-coagulation factor xi antibodies - Google Patents

Anti-coagulation factor xi antibodies

Info

Publication number
PH12018502586A1
PH12018502586A1 PH12018502586A PH12018502586A PH12018502586A1 PH 12018502586 A1 PH12018502586 A1 PH 12018502586A1 PH 12018502586 A PH12018502586 A PH 12018502586A PH 12018502586 A PH12018502586 A PH 12018502586A PH 12018502586 A1 PH12018502586 A1 PH 12018502586A1
Authority
PH
Philippines
Prior art keywords
coagulation factor
antibodies
activation
fxia
fxi
Prior art date
Application number
PH12018502586A
Other languages
English (en)
Inventor
Zhu Chen
Kenneth P Ellsworth
James Milligan
Elizabeth Oldham
Dietmar; Seiffert
Vaishnavi Ganti
Mohammad; Tabrizifard
Bianka Prinz
Original Assignee
Merck Sharp & Dohme
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Adimab Llc filed Critical Merck Sharp & Dohme
Publication of PH12018502586A1 publication Critical patent/PH12018502586A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
PH12018502586A 2016-06-14 2018-12-06 Anti-coagulation factor xi antibodies PH12018502586A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Publications (1)

Publication Number Publication Date
PH12018502586A1 true PH12018502586A1 (en) 2019-10-07

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502586A PH12018502586A1 (en) 2016-06-14 2018-12-06 Anti-coagulation factor xi antibodies

Country Status (29)

Country Link
US (6) US10676536B2 (enExample)
EP (1) EP3469002A1 (enExample)
JP (2) JP7022081B2 (enExample)
KR (2) KR102379580B1 (enExample)
CN (2) CN109476758B (enExample)
AR (1) AR108717A1 (enExample)
AU (3) AU2017286432B2 (enExample)
BR (1) BR112018075858A2 (enExample)
CA (2) CA3025869C (enExample)
CL (2) CL2018003565A1 (enExample)
CO (1) CO2018013434A2 (enExample)
CR (1) CR20180583A (enExample)
DO (1) DOP2018000284A (enExample)
EA (1) EA201892716A1 (enExample)
EC (1) ECSP18091593A (enExample)
GE (1) GEP20227382B (enExample)
IL (2) IL263272B2 (enExample)
JO (1) JOP20180121A1 (enExample)
MA (1) MA45234A (enExample)
MX (2) MX2018015757A (enExample)
MY (1) MY201852A (enExample)
NI (1) NI201800134A (enExample)
PE (1) PE20190416A1 (enExample)
PH (1) PH12018502586A1 (enExample)
SG (2) SG10202103120UA (enExample)
TN (1) TN2018000417A1 (enExample)
TW (2) TWI802193B (enExample)
UA (1) UA129793C2 (enExample)
WO (1) WO2017218371A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EA201892716A1 (ru) * 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN114269790B (zh) * 2020-07-02 2023-11-24 北京拓界生物医药科技有限公司 抗FXI/FXIa抗体、其抗原结合片段及医药用途
JP2023531278A (ja) * 2020-07-03 2023-07-21 スチョー アルファマブ カンパニー リミテッド 凝固第ｘｉ因子（ｆｘｉ）結合タンパク質
IL304971A (en) * 2021-02-09 2023-10-01 Arxx Therapeutics As Humanized anti-S100A4 antibody, uses and methods
CN116199782A (zh) * 2021-11-30 2023-06-02 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法
WO2024141099A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
ATE113846T1 (de) 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
WO2006069036A2 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
UA115960C2 (uk) 2003-07-15 2018-01-25 Емджен, Інк., Людські анти-ngf нейтралізуючі антитіла як селективні інгібітори метаболічних шляхів фактора росту нервової тканини (ngf)
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
HRP20120701T1 (hr) 2005-12-08 2012-10-31 Medarex, Inc. Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
SG177194A1 (en) 2005-12-08 2012-01-30 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
KR20220031126A (ko) 2006-06-06 2022-03-11 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
WO2008112004A2 (en) * 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TW200927761A (en) 2007-09-26 2009-07-01 U3 Pharma Ag Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EP3002298B1 (en) * 2007-11-21 2019-08-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
DK2297207T3 (en) 2008-06-19 2018-12-03 Prothix Bv USING ANTI-FACTOR XI ANTIBODIES FOR PREVENTION OR TREATMENT OF THROME CREATION
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
DK2350304T3 (en) 2008-10-31 2017-03-13 Janssen Biotech Inc TOLL-LIKE RECEPTOR 3-ANTAGONISTS
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
ES2720594T3 (es) 2008-12-18 2019-07-23 Univ Oregon Health & Science Anticuerpos anti-fXI y métodos de uso
US20120114667A1 (en) * 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
EP2918602A1 (en) 2009-04-16 2015-09-16 AbbVie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
PL2426148T3 (pl) 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
WO2011045704A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
WO2011079004A1 (en) 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
US20110244826A1 (en) * 2010-02-03 2011-10-06 Subramaniyan Krishnan Mobile communication plan offerings
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
CA2815154A1 (en) * 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
CA2818548A1 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
HUE031089T2 (en) 2012-04-13 2017-06-28 Rottapharm Biotech Srl Anti-ADAMTS-5 antibody, derivatives and uses
SG10201609322QA (en) * 2012-05-10 2017-01-27 Bayer Pharma AG Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
HK1208474A1 (en) 2012-05-17 2016-03-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind egfr
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3052523B1 (en) * 2013-10-01 2021-03-10 Medimmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
CN106661568A (zh) 2014-03-20 2017-05-10 日本国立感染症研究所 对丙型肝炎病毒具有感染抑制活性的抗体
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
PL3280441T3 (pl) 2015-04-07 2022-02-21 Alector Llc Przeciwciała przeciwko sortilinie i sposoby ich stosowania
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
CA3010224A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
AU2017329645A1 (en) 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof

Also Published As

Publication number Publication date
KR102218714B1 (ko) 2021-02-24
SG10202103120UA (en) 2021-05-28
IL315266A (en) 2024-10-01
US12275800B2 (en) 2025-04-15
JP2021101720A (ja) 2021-07-15
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
KR20190018504A (ko) 2019-02-22
AU2017286432A1 (en) 2018-12-06
US20170355780A1 (en) 2017-12-14
TWI752964B (zh) 2022-01-21
JP7022081B2 (ja) 2022-02-17
ECSP18091593A (es) 2019-01-31
WO2017218371A1 (en) 2017-12-21
JP7277500B2 (ja) 2023-05-19
NI201800134A (es) 2019-03-05
CN116425879A (zh) 2023-07-14
NZ786442A (en) 2025-06-27
UA129793C2 (uk) 2025-08-06
JP2019521978A (ja) 2019-08-08
MX2018015757A (es) 2019-05-30
US11479615B2 (en) 2022-10-25
NZ786447A (en) 2025-06-27
CL2018003565A1 (es) 2019-03-22
CO2018013434A2 (es) 2018-12-28
AU2020210233A1 (en) 2020-08-20
US11661460B2 (en) 2023-05-30
TN2018000417A1 (en) 2020-06-15
US20200317811A1 (en) 2020-10-08
PE20190416A1 (es) 2019-03-19
US11485794B2 (en) 2022-11-01
IL263272B1 (en) 2025-03-01
NZ786443A (en) 2025-06-27
TW202214702A (zh) 2022-04-16
MY201852A (en) 2024-03-20
US20200255542A1 (en) 2020-08-13
NZ786444A (en) 2025-06-27
US20200270364A1 (en) 2020-08-27
AR108717A1 (es) 2018-09-19
MX2023012740A (es) 2024-02-23
CR20180583A (es) 2019-07-02
CN109476758A (zh) 2019-03-15
IL263272A (en) 2018-12-31
TW201802120A (zh) 2018-01-16
MA45234A (fr) 2019-04-17
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
TWI802193B (zh) 2023-05-11
JOP20180121A1 (ar) 2018-12-12
CA3025869A1 (en) 2017-12-21
CA3172367A1 (en) 2017-12-21
GEP20227382B (en) 2022-05-25
EP3469002A1 (en) 2019-04-17
KR102379580B1 (ko) 2022-03-29
AU2017286432B2 (en) 2020-09-24
CL2024000367A1 (es) 2024-08-23
DOP2018000284A (es) 2019-01-31
CA3025869C (en) 2025-10-07
NZ786448A (en) 2025-06-27
BR112018075858A2 (pt) 2019-04-02
SG11201810763TA (en) 2018-12-28
IL263272B2 (en) 2025-07-01
US11512142B2 (en) 2022-11-29
US20200308302A1 (en) 2020-10-01
KR20210021124A (ko) 2021-02-24
AU2020210233B2 (en) 2024-03-07
NZ748743A (en) 2025-06-27
EA201892716A1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
MX2021000027A (es) Anticuerpos anti-factor de la coagulacion xi.
PH12018502586A1 (en) Anti-coagulation factor xi antibodies
PH12019502283A1 (en) Anti-lag3 antibodies
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
EA201691541A1 (ru) Новые анти-baff антитела
NZ746609A (en) Ilt7 binding molecules and methods of using the same
WO2017139664A8 (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG10201806454RA (en) Anti-tenascin c antibodies and uses thereof
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA201990694A1 (ru) Композиции для лечения деменции
MX374569B (es) Compuestos organolépticos novedosos.
EA202090552A1 (ru) Активируемые антитела к cd166 и способы их применения
MX368075B (es) Compuestos organolepticos novedosos.
MX380297B (es) Compuestos organolépticos novedosos.